Front Cover: Development of Carborane-Based Halogenated Naphthyridinone-Analogues as Cannabinoid Receptor Type 2 (CB2R) Ligands (ChemMedChem 17/2025)

IF 3.4 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-09-18 DOI:10.1002/cmdc.70021

Lea Ueberham, Winnie Deuther-Conrad, Peter Lönnecke, Aleksandr Kazimir, Evamarie Hey-Hawkins

引用次数: 0

Abstract

An icosahedral glimmer in the dark: Carborane-modified halogenated naphthyridinones illuminate the path towards CB₂R-selective PET imaging agents, with a brown (bromine) and a purple (iodine) companion. The determination of CB₂R overexpression in pathological conditions with PET requires radiotracers. In article 10.1002/cmdc.202500251, Evamarie Hey-Hawkins and co-workers report carborane-based CB₂R ligands with different carborane isomers and halogene substituents as potential CB₂R-PET tracers. Art by Dr. Christoph Selg.

Abstract Image

查看原文本刊更多论文

封面：碳硼烷基卤化萘嘧啶类似物作为大麻素受体2型（CB2R）配体的发展（ChemMedChem 17/2025）

黑暗中的二十面体微光：碳硼烷修饰的卤化萘啶酮照亮了cb2r选择性PET显像剂的路径，棕色（溴）和紫色（碘）伴生物。用PET测定病理状态下CB2R过表达需要放射性示踪剂。见第10.1002/cmdc条。202500251， Evamarie Hey-Hawkins及其同事报道了具有不同碳硼烷异构体和卤素取代基的碳硼烷基CB2R配体作为潜在的CB2R- pet示踪剂。Christoph Selg博士的艺术作品。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.